Info
Algae in Diabetes Management : Therapeutic Properties and Applications
| Algae in Diabetes Management : Therapeutic Properties and Applications |
| Autore | Raja Rathinam |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Singapore : , : Springer, , 2025 |
| Descrizione fisica | 1 online resource (601 pages) |
| Disciplina | 616.46206 |
| Altri autori (Persone) |
HemaiswaryaShanmugam
SanjivkumarMuthusamy SilambarasanTamil Selvan ImmanuelGrasian |
| Collana | Biomedical and Life Sciences Series |
| ISBN | 981-9505-71-2 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9911028744203321 |
Raja Rathinam
|
||
| Singapore : , : Springer, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
App Use and Patient Empowerment in Diabetes Self-Management : Advancing Theory-Guided mHealth Research / / by Nicola Brew-Sam
| App Use and Patient Empowerment in Diabetes Self-Management : Advancing Theory-Guided mHealth Research / / by Nicola Brew-Sam |
| Autore | Brew-Sam Nicola |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Wiesbaden : , : Springer Fachmedien Wiesbaden : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (XXIV, 303 p. 11 illus., 1 illus. in color.) |
| Disciplina | 616.46206 |
| Soggetto topico |
Diabetes
Medical informatics Health Informatics |
| ISBN |
9783658293574
3658293578 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Defining and Categorizing Diabetes Apps for Self-Management -- Anteceding Factors of Diabetes App Use -- Empowerment and its Relevance for Diabetes Management. |
| Record Nr. | UNINA-9910380735203321 |
|
Brew-Sam Nicola
|
||
| Wiesbaden : , : Springer Fachmedien Wiesbaden : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ATTD 2011 Year Book : Advanced Technologies and Treatments for Diabetes / / edited by Moshe Phillip, Tadej Battelino
| ATTD 2011 Year Book : Advanced Technologies and Treatments for Diabetes / / edited by Moshe Phillip, Tadej Battelino |
| Edizione | [3rd ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, UK ; ; Hoboken, N.J., : John Wiley & Sons, 2012 |
| Descrizione fisica | 1 online resource (298 p.) |
| Disciplina |
616.462
616.46206 |
| Altri autori (Persone) |
PhillipMoshe
BattelinoTadej |
| Soggetto topico |
Diabetes - Treatment
Diabetics - Rehabilitation |
| ISBN |
1-280-58787-3
9786613617705 1-118-32151-0 1-118-32150-2 1-118-32152-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ATTD 2011 Yearbook; Contents; List of Contributors; Preface; CHAPTER 1 Self-Monitoring of Blood Glucose; CHAPTER 2 Continuous Glucose Monitoring in 2011; CHAPTER 3 Insulin Pumps; CHAPTER 4 Closing the Loop; CHAPTER 5 New Insulins and Insulin Therapy; CHAPTER 6 New Ways of Insulin Delivery; CHAPTER 7 Using Health Information Technology to Prevent and Treat Diabetes; CHAPTER 8 Technology and Pregnancy; CHAPTER 9 Type 1 Diabetes Mellitus: Immune Intervention; CHAPTER 10 Advances in Exercise, Physical Activity and Diabetes Mellitus
CHAPTER 11 Diabetes Technology and Treatment in the Paediatric Age GroupCHAPTER 12 Diabetes Technology and the Human Factor; CHAPTER 13 New Medications for the Treatment of Diabetes; Index |
| Altri titoli varianti | Advanced Technologies and Treatments for Diabetes 2011 yearbook |
| Record Nr. | UNINA-9910141343103321 |
| Chichester, West Sussex, UK ; ; Hoboken, N.J., : John Wiley & Sons, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Behavioral programs for diabetes mellitus / / Jennifer Pillay [and eleven others], editors
| Behavioral programs for diabetes mellitus / / Jennifer Pillay [and eleven others], editors |
| Autore | Pillay Jennifer |
| Pubbl/distr/stampa | Rockville, MD : , : Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, , 2015 |
| Descrizione fisica | 1 online resource (310 pages) : illustrations |
| Disciplina | 616.46206 |
| Collana | Evidence report/technology assessment |
| Soggetto topico | Diabetes - Treatment |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910714992703321 |
|
Pillay Jennifer
|
||
| Rockville, MD : , : Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Complementary therapies and the management of diabetes and vascular disease [[electronic resource] ] : a matter of balance / / editor, Trish Dunning
| Complementary therapies and the management of diabetes and vascular disease [[electronic resource] ] : a matter of balance / / editor, Trish Dunning |
| Pubbl/distr/stampa | Chichester ; ; New York, : J. Wiley, c2006 |
| Descrizione fisica | 1 online resource (422 p.) |
| Disciplina |
616.462
616.46206 |
| Altri autori (Persone) | DunningTrisha |
| Collana | Diabetes in practice |
| Soggetto topico | Diabetes - Alternative treatment |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-73987-8
9786610739875 0-470-05743-2 0-470-05742-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Complementary Therapies and the Management of Diabetes and Vascular Disease; Contents; Preface; Foreword; List of Contributors; Acknowledgements; 1 Introduction to Diabetes; 1.1 Incidence and Prevalence of Diabetes; 1.2 Overview of Diabetes; 1.3 Management Strategies; 1.4 Management Targets and Regimens; 1.5 Short-term Complications; 1.6 Long-term Complications; 1.7 Psychological Aspects; 1.8 Diabetes Management Requires Integrated Approaches; 1.9 People with Diabetes' Needs, Capacities and Resources; 1.10 Health Professionals' Needs; 1.11 Integration - Is It Possible?
1.12 Complementary Therapies1.13 Summary; References; 2 Complementary Therapy Use; 2.1 Introduction; 2.2 Defining Complementary Therapies; 2.3 What Is Traditional Use?; 2.4 Philosophical Basis of CAM; 2.5 Frequency of CAM Use; 2.6 Profile of Likely CAM Users; 2.7 Culture, Health Beliefs and CAM; 2.8 Reported Adverse Events Associated with CAM; 2.9 Summary; References; 3 Complementary Medicine and Safety; 3.1 Introduction; 3.2 Practices; 3.3 Risks and safety; 3.4 Adverse Events; 3.5 Intrinsic and Extrinsic Factors; 3.6 Pre-market Safety Mechanisms; 3.7 Preventing Adverse Medicine Reactions 3.8 Safety of CM and Diabetes ManagementReferences; 4 Integrating Complementary and Conventional Therapies; 4.1 Introduction; 4.2 What is Integration?; 4.3 Concerns about Integration; 4.4 Benefits of Integration; 4.5 Obstacles to Integration; 4.6 How Can Integration Be Achieved?; 4.7 Current Integrative Models; 4.8 Regulatory Issues; 4.9 Responsibilities of Individual Conventional Practitioners Using Complementary Therapies; 4.10 Evidence-based Care and Clinical Practice Guidelines; 4.11 Guidelines for Patients Using Complementary Therapies; 4.12 Quality Use of Medicines 4.13 Documentation and communication4.14 Adverse event reporting; References; 5 Nutritional Therapies; 5.1 Introduction; 5.2 Nutritional Medicine (NM); 5.3 Nutritional Medicine Assessment Approaches; 5.4 The Zone Diet; 5.5 Total Wellbeing Diet; 5.6 Ketogenic or Atkins Diet; 5.7 Metabolic Typing and ABO Blood Type Diets; 5.8 ABO Blood Type Diet; 5.9 The USDA Food Guide Pyramid; 5.10 Detoxification Diets; 5.11 Nutritional Supplementation; 5.12 Vitamins; 5.13 Minerals; 5.15 Essential Fatty Acids; Gamma-Linolenic Acid and Omega 3 Fish Oils; 5.16 Other Key Nutrients; 5.17 Safe Use of Supplements References6 Essential Oils (Aromatherapy); 6.1 Introduction; 6.2 Aromatherapy Care Models; 6.3 Essential Oils; 6.4 Essential Oils and Diabetes Education and Management; 6.5 Precautions to Consider When Assessing the Suitability of Essential Oils in Patients with Renal Disease; 6.6 Essential Oil Use; 6.7 Mental Health and Psychological Care; 6.8 Essential Oil Application/Administration Methods; 6.9 Essential Oil Safety Issues; 6.10 Essential Oil - Conventional Medicine Interactions; References; 7 Counselling and Relaxation Therapies; 7.1 Introduction; 7.2 The Body and the Mind 7.3 Diabetes and the Psyche |
| Record Nr. | UNINA-9910143710903321 |
| Chichester ; ; New York, : J. Wiley, c2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Complementary therapies and the management of diabetes and vascular disease [[electronic resource] ] : a matter of balance / / editor, Trish Dunning
| Complementary therapies and the management of diabetes and vascular disease [[electronic resource] ] : a matter of balance / / editor, Trish Dunning |
| Pubbl/distr/stampa | Chichester ; ; New York, : J. Wiley, c2006 |
| Descrizione fisica | 1 online resource (422 p.) |
| Disciplina |
616.462
616.46206 |
| Altri autori (Persone) | DunningTrisha |
| Collana | Diabetes in practice |
| Soggetto topico | Diabetes - Alternative treatment |
| ISBN |
1-280-73987-8
9786610739875 0-470-05743-2 0-470-05742-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Complementary Therapies and the Management of Diabetes and Vascular Disease; Contents; Preface; Foreword; List of Contributors; Acknowledgements; 1 Introduction to Diabetes; 1.1 Incidence and Prevalence of Diabetes; 1.2 Overview of Diabetes; 1.3 Management Strategies; 1.4 Management Targets and Regimens; 1.5 Short-term Complications; 1.6 Long-term Complications; 1.7 Psychological Aspects; 1.8 Diabetes Management Requires Integrated Approaches; 1.9 People with Diabetes' Needs, Capacities and Resources; 1.10 Health Professionals' Needs; 1.11 Integration - Is It Possible?
1.12 Complementary Therapies1.13 Summary; References; 2 Complementary Therapy Use; 2.1 Introduction; 2.2 Defining Complementary Therapies; 2.3 What Is Traditional Use?; 2.4 Philosophical Basis of CAM; 2.5 Frequency of CAM Use; 2.6 Profile of Likely CAM Users; 2.7 Culture, Health Beliefs and CAM; 2.8 Reported Adverse Events Associated with CAM; 2.9 Summary; References; 3 Complementary Medicine and Safety; 3.1 Introduction; 3.2 Practices; 3.3 Risks and safety; 3.4 Adverse Events; 3.5 Intrinsic and Extrinsic Factors; 3.6 Pre-market Safety Mechanisms; 3.7 Preventing Adverse Medicine Reactions 3.8 Safety of CM and Diabetes ManagementReferences; 4 Integrating Complementary and Conventional Therapies; 4.1 Introduction; 4.2 What is Integration?; 4.3 Concerns about Integration; 4.4 Benefits of Integration; 4.5 Obstacles to Integration; 4.6 How Can Integration Be Achieved?; 4.7 Current Integrative Models; 4.8 Regulatory Issues; 4.9 Responsibilities of Individual Conventional Practitioners Using Complementary Therapies; 4.10 Evidence-based Care and Clinical Practice Guidelines; 4.11 Guidelines for Patients Using Complementary Therapies; 4.12 Quality Use of Medicines 4.13 Documentation and communication4.14 Adverse event reporting; References; 5 Nutritional Therapies; 5.1 Introduction; 5.2 Nutritional Medicine (NM); 5.3 Nutritional Medicine Assessment Approaches; 5.4 The Zone Diet; 5.5 Total Wellbeing Diet; 5.6 Ketogenic or Atkins Diet; 5.7 Metabolic Typing and ABO Blood Type Diets; 5.8 ABO Blood Type Diet; 5.9 The USDA Food Guide Pyramid; 5.10 Detoxification Diets; 5.11 Nutritional Supplementation; 5.12 Vitamins; 5.13 Minerals; 5.15 Essential Fatty Acids; Gamma-Linolenic Acid and Omega 3 Fish Oils; 5.16 Other Key Nutrients; 5.17 Safe Use of Supplements References6 Essential Oils (Aromatherapy); 6.1 Introduction; 6.2 Aromatherapy Care Models; 6.3 Essential Oils; 6.4 Essential Oils and Diabetes Education and Management; 6.5 Precautions to Consider When Assessing the Suitability of Essential Oils in Patients with Renal Disease; 6.6 Essential Oil Use; 6.7 Mental Health and Psychological Care; 6.8 Essential Oil Application/Administration Methods; 6.9 Essential Oil Safety Issues; 6.10 Essential Oil - Conventional Medicine Interactions; References; 7 Counselling and Relaxation Therapies; 7.1 Introduction; 7.2 The Body and the Mind 7.3 Diabetes and the Psyche |
| Record Nr. | UNINA-9910830285203321 |
| Chichester ; ; New York, : J. Wiley, c2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode]
| Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode] |
| Pubbl/distr/stampa | London, : Novartis Foundation, 2008 |
| Descrizione fisica | 1 online resource (224 p.) |
| Disciplina | 616.46206 |
| Collana | Novartis Foundation symposium |
| Soggetto topico |
Diabetes - Immunotherapy
Diabetes - Treatment |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-84052-1
9786611840525 0-470-69740-7 0-470-69741-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Defining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes
CD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject index |
| Record Nr. | UNINA-9910144093303321 |
| London, : Novartis Foundation, 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode]
| Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode] |
| Pubbl/distr/stampa | London, : Novartis Foundation, 2008 |
| Descrizione fisica | 1 online resource (224 p.) |
| Disciplina | 616.46206 |
| Collana | Novartis Foundation symposium |
| Soggetto topico |
Diabetes - Immunotherapy
Diabetes - Treatment |
| ISBN |
1-281-84052-1
9786611840525 0-470-69740-7 0-470-69741-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Defining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes
CD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject index |
| Record Nr. | UNISA-996217070603316 |
| London, : Novartis Foundation, 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode]
| Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode] |
| Pubbl/distr/stampa | London, : Novartis Foundation, 2008 |
| Descrizione fisica | 1 online resource (224 p.) |
| Disciplina | 616.46206 |
| Collana | Novartis Foundation symposium |
| Soggetto topico |
Diabetes - Immunotherapy
Diabetes - Treatment |
| ISBN |
1-281-84052-1
9786611840525 0-470-69740-7 0-470-69741-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Defining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes
CD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject index |
| Record Nr. | UNINA-9910830043703321 |
| London, : Novartis Foundation, 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Defining optimal immunotherapies for type 1 diabetes / / [editors: Gregory Bock and Jamie Goode]
| Defining optimal immunotherapies for type 1 diabetes / / [editors: Gregory Bock and Jamie Goode] |
| Pubbl/distr/stampa | London, : Novartis Foundation, 2008 |
| Descrizione fisica | 1 online resource (224 p.) |
| Disciplina | 616.46206 |
| Collana | Novartis Foundation symposium |
| Soggetto topico |
Diabetes - Immunotherapy
Diabetes - Treatment |
| ISBN |
9786611840525
9781281840523 1281840521 9780470697405 0470697407 9780470697412 0470697415 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Defining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes
CD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject index |
| Record Nr. | UNINA-9911019280003321 |
| London, : Novartis Foundation, 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||